Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Clinical data at baseline and at 3 months

From: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

  Responders Non-responders
  Subset 1 Subset 2 Subset 1 Subset 2
  Baseline 3 monthsa Baseline 3 monthsa Baseline 3 monthsa Baseline 3 monthsa
Morning stiffness (minutes)b 245 ± 126c 35 ± 24.5c 210 ± 81 58 ± 70.2c 179 ± 159 66.4 ± 86c 133 ± 84 62 ± 67.6c
DAS28 b 6.4 ± 1.0 4.2 ± 0.9c 6.2 ± 0.7 3.8 ± 0.6c 5.7 ± 0.8 5.3 ± 1.0 5.5 ± 1.0 4.9 ± 1.0c
Pain (0–100 mm VAS) 59.3 ± 20.3 29.3 ± 9.3c 62.5 ± 15.5 31.3 ± 14.5c 69.3 ± 13.1 54.1 ± 22.1 60.9 ± 11.4 40.6 ± 18.4c
ESR (mm/hour) 44 ± 26.2 27 ± 20.3c 27.2 ± 15.7 11.3 ± 5.2c 35.7 ± 25.7 28.3 ± 15.3 24.1 ± 11.5 27.8 ± 19.2
CRP (mg/l)b 42 ± 29.8 20 ± 15.7c 28.6 ± 19.7 6.2 ± 6.1c 18.5 ± 12.7 13 ± 8.2 15.8 ± 15.6 11 ± 7.3
HAQ score (0–3 scale) 1.6 ± 0.4 0.9 ± 0.5c 1.8 ± 0.7 1.2 ± 0.7c 1.6 ± 0.4 1.2 ± 0.3 1.5 ± 0.4 1.5 ± 0.4
  1. Values are mean ± standard deviation. aResponse assessed just before the fourth infliximab/methotrexate infusion. Significant differences between groups are as follows: bdifference between all responders versus non-responders at baseline (0.03 <p < 0.05, Mann and Whitney's test); other comparisons were non-significant (p = 0.58); cDifference at baseline versus 3 months in this subset (p < 0.05, paired Wilcoxon's test). CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; VAS, visual analogue scale (patient's assessment of pain).